Index: ABCDEFGHIJKLMNOPQRSTUVWXYZ
| Active pharmaceutical ingredient (API) /active ingredient | Approval |
| Audit | AVWG |
| BfArM | Bioequivalence |
| Biopharmaceuticals | Biosimilars |
| Bio-study | BMGS |
| Branded products |
| Centralized approval procedure | Commercial business |
| Commercial property rights | Co-payment |
| Cost bearer |
| Data exclusivity period | Decentralized European approval procedure |
| Dialysis | Dossier |
| Early entry | EMEA |
| Erythropoietin (abbreviation Epo) |
| FDA | Filgrastim |
| Freely-available drugs |
| Generics | GKV |
| GKV market | GKV-WSG |
| GMG | GMP |
| Health care products |
| Indication | Initial supplier |
| INN (International Non-proprietary Name) generics |
| Manufacturing permit | Monoclonal antibody |
| MR procedure | Multiple ownership |
| Multisource products |
| NDA approval | Non-pharmacist ownership |
| Oncology | Orphan Drug |
| OTC market | OTX products |
| Patent | Pharmaceutical production |
| Pharmacovigilance | Pharmacy-only drugs |
| Prescription market | Prescription obligation |
| Protein |
| Reference pricing |
| Second supplier | Self-medication market |
| SPC | Subsequent approval |
| Therapeutics Advertising Act |